Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 26, 2024, details a public equity offering consummated by Theriva Biologics, Inc. on September 27, 2024. The company, incorporated in Nevada and headquartered in Rockville, Maryland, is an emerging growth company focused on biologics.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $2.5 million raised from the offering.
- Securities Issued:
- 918,600 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 510,000 shares of Common Stock.
- Common Stock purchase warrants to purchase up to 1,428,600 shares of Common Stock.
- Offering Price: $1.75 per share for Common Stock and associated Common Warrants; $1.7499 per Pre-Funded Warrant and associated Common Warrant.
- Transaction Costs: Placement agent fee of 7.0% of gross proceeds; reimbursement of up to $100,000 for legal and out-of-pocket expenses.
- Outstanding Shares: 2,272,462 shares of Common Stock outstanding immediately following the closing (excluding warrant exercises).
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and the issuance of warrants. The company intends to use the net proceeds primarily for working capital and general corporate purposes. Specific allocations include research and development, manufacturing scale-up, and potential investments in or acquisitions of other products, businesses, or technologies.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or revenue outlook. However, it outlines significant contractual restrictions:
- Lock-Up Periods: The Company is restricted from issuing new equity for 60 days. Executive officers and directors are subject to a 90-day lock-up period.
- ATM Restrictions: The Company cannot engage in "at-the-market" or continuous equity offerings for six months, with an exception for the existing ATM facility with the placement agent after 45 days.
- Warrant Terms: Common Warrants have an exercise price of $2.00 and expire in five years. Pre-Funded Warrants are immediately exercisable at $0.0001. Both include beneficial ownership limitations (4.99% or 9.99% caps).
Investor Verification Checklist
- Verify the net proceeds after deducting the 7.0% placement fee and the $100,000 expense cap.
- Confirm the dilution impact of the 1,428,600 Common Warrants and 510,000 Pre-Funded Warrants on future share counts.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Monitor the company's cash burn rate relative to the $2.5 million raised to assess runway for R&D and manufacturing scale-up.